SG11201504422XA - Transmucosal delivery of glatiramer acetate - Google Patents
Transmucosal delivery of glatiramer acetateInfo
- Publication number
- SG11201504422XA SG11201504422XA SG11201504422XA SG11201504422XA SG11201504422XA SG 11201504422X A SG11201504422X A SG 11201504422XA SG 11201504422X A SG11201504422X A SG 11201504422XA SG 11201504422X A SG11201504422X A SG 11201504422XA SG 11201504422X A SG11201504422X A SG 11201504422XA
- Authority
- SG
- Singapore
- Prior art keywords
- glatiramer acetate
- transmucosal delivery
- transmucosal
- delivery
- glatiramer
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/03—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nutrition Science (AREA)
- Immunology (AREA)
- Physiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261745226P | 2012-12-21 | 2012-12-21 | |
| PCT/US2013/077034 WO2014100639A1 (en) | 2012-12-21 | 2013-12-20 | Transmucosal delivery of glatiramer acetate |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201504422XA true SG11201504422XA (en) | 2015-07-30 |
Family
ID=50979257
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201504422XA SG11201504422XA (en) | 2012-12-21 | 2013-12-20 | Transmucosal delivery of glatiramer acetate |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20160193276A1 (en) |
| EP (1) | EP2934492A4 (en) |
| JP (1) | JP2016503803A (en) |
| KR (1) | KR20150111918A (en) |
| CN (1) | CN104869983A (en) |
| AU (1) | AU2013361053A1 (en) |
| BR (1) | BR112015014095A2 (en) |
| CA (1) | CA2895359A1 (en) |
| EA (1) | EA201591188A1 (en) |
| HK (2) | HK1214134A1 (en) |
| IL (1) | IL239280A0 (en) |
| MX (1) | MX2015007678A (en) |
| SG (1) | SG11201504422XA (en) |
| WO (1) | WO2014100639A1 (en) |
| ZA (1) | ZA201505049B (en) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8709433B2 (en) | 2010-10-11 | 2014-04-29 | Teva Pharmaceutical Industries Ltd. | Cytokine biomarkers as predictive biomarkers of clinical response for Glatiramer acetate |
| AU2012323345A1 (en) | 2011-10-10 | 2014-05-22 | Teva Pharmaceutical Industries Ltd. | Single nucleotide polymorphisms useful to predict clinical response for glatiramer acetate |
| UY35790A (en) | 2013-10-21 | 2015-05-29 | Teva Pharma | GENETIC MARKERS THAT PREACH THE RESPONSE TO THE GLATIRAMER ACETATE |
| WO2015140790A1 (en) | 2014-03-17 | 2015-09-24 | Mapi Pharma Ltd. | Sublingual delivery of glatiramer acetate |
| CN106924175B (en) * | 2015-12-29 | 2020-07-03 | 深圳翰宇药业股份有限公司 | Pharmaceutical composition for treating multiple sclerosis |
| CN108601737A (en) * | 2016-02-12 | 2018-09-28 | 特华制药株式会社 | Dry granulation object and the solid formulation containing the dry granulation object and its manufacturing method |
| JP2020525459A (en) | 2017-06-26 | 2020-08-27 | アンスティテュ・パストゥール | Treatment to eliminate HIV reservoir and reduce viral load |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL150895A0 (en) * | 2000-02-18 | 2003-02-12 | Teva Pharma | Oral, nasal and pulmonary formulations of copolymer-1 |
| ZA200206457B (en) * | 2000-02-18 | 2003-08-13 | Yeda Res & Dev | Oral, nasal and pulmonary dosage formulations of copolymer 1. |
| CA2448558A1 (en) * | 2001-07-10 | 2003-01-23 | Teva Pharmaceutical Industries, Ltd. | Drug delivery system for zero order, zero order-biphasic, ascending or descending drug delivery |
| EP1848415B1 (en) * | 2005-02-17 | 2013-04-03 | Teva Pharmaceutical Industries, Ltd. | Combination therapy with glatiramer acetate and rasagiline for the treatment of multiple sclerosis |
| WO2007061415A1 (en) * | 2005-11-22 | 2007-05-31 | Teva Pharmaceutical Industries Ltd. | Pharmaceutical compositions of telmisartan |
| EP1978939A2 (en) * | 2005-12-27 | 2008-10-15 | Jubilant Organosys Limited | Mouth dissolving pharmaceutical composition and process for preparing the same using a high amount of silicon dioxine |
| KR101315610B1 (en) * | 2006-09-22 | 2013-10-10 | 파마시클릭스, 인코포레이티드 | Inhibitors of bruton's tyrosine kinase |
| ES2329327B1 (en) * | 2008-03-19 | 2010-09-17 | Proyecto De Biomedicina Cima, S.L. | 5'-METHYLTIOADENOSINE SYNERGIC COMBINATIONS. |
-
2013
- 2013-12-20 EP EP13865051.0A patent/EP2934492A4/en not_active Withdrawn
- 2013-12-20 SG SG11201504422XA patent/SG11201504422XA/en unknown
- 2013-12-20 CA CA2895359A patent/CA2895359A1/en not_active Abandoned
- 2013-12-20 BR BR112015014095A patent/BR112015014095A2/en not_active IP Right Cessation
- 2013-12-20 JP JP2015549792A patent/JP2016503803A/en not_active Withdrawn
- 2013-12-20 AU AU2013361053A patent/AU2013361053A1/en not_active Abandoned
- 2013-12-20 CN CN201380067083.XA patent/CN104869983A/en active Pending
- 2013-12-20 US US14/653,022 patent/US20160193276A1/en not_active Abandoned
- 2013-12-20 EA EA201591188A patent/EA201591188A1/en unknown
- 2013-12-20 KR KR1020157019729A patent/KR20150111918A/en not_active Application Discontinuation
- 2013-12-20 WO PCT/US2013/077034 patent/WO2014100639A1/en active Application Filing
- 2013-12-20 MX MX2015007678A patent/MX2015007678A/en unknown
-
2015
- 2015-06-08 IL IL239280A patent/IL239280A0/en unknown
- 2015-07-14 ZA ZA2015/05049A patent/ZA201505049B/en unknown
-
2016
- 2016-02-23 HK HK16102020.2A patent/HK1214134A1/en unknown
- 2016-03-07 HK HK16102544.9A patent/HK1214523A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20150111918A (en) | 2015-10-06 |
| US20160193276A1 (en) | 2016-07-07 |
| IL239280A0 (en) | 2015-07-30 |
| EP2934492A1 (en) | 2015-10-28 |
| EP2934492A4 (en) | 2016-08-17 |
| ZA201505049B (en) | 2016-10-26 |
| HK1214523A1 (en) | 2016-07-29 |
| JP2016503803A (en) | 2016-02-08 |
| CA2895359A1 (en) | 2014-06-26 |
| AU2013361053A1 (en) | 2015-07-30 |
| EA201591188A1 (en) | 2016-04-29 |
| BR112015014095A2 (en) | 2017-07-11 |
| CN104869983A (en) | 2015-08-26 |
| MX2015007678A (en) | 2015-09-07 |
| HK1214134A1 (en) | 2016-07-22 |
| WO2014100639A1 (en) | 2014-06-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1215817A1 (en) | Content delivery framework | |
| ZA201502352B (en) | Liposomal drug delivery system | |
| EP2683431A4 (en) | Medicant delivery system | |
| IL236268A0 (en) | Compositions for transmucosal delivery and uses thereof | |
| HK1208155A1 (en) | Transmucosal delivery of engineered polypeptides | |
| EP2836982A4 (en) | Digital content delivery | |
| HK1214523A1 (en) | Transmucosal delivery of glatiramer acetate | |
| HK1207295A1 (en) | Transmucosal delivery of tocotrienol | |
| HK1202826A1 (en) | Medicament delivery devices | |
| HK1215529A1 (en) | Oral transmucosal drug delivery system | |
| AU2013344654A1 (en) | Oral transmucosal drug delivery system | |
| GB201213491D0 (en) | Content delivery system | |
| HK1202827A1 (en) | Improvements relating to medicament delivery devices | |
| IL229425B (en) | Drug delivery system | |
| HK1214522A1 (en) | Oral transmucosal delivery of glatiramer acetate | |
| HK1215668A1 (en) | Caspofungin acetate formulations | |
| EP2926712A4 (en) | Gas delivery system | |
| SG10201609440WA (en) | Multi-additive delivery system | |
| PL2908837T3 (en) | Compositions for drug delivery | |
| SG11201405743QA (en) | Liposomal delivery system | |
| GB201121693D0 (en) | Medicament delivery technology |